Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial
Sign Up to like & getrecommendations! Published in 2025 at "Diabetes"
DOI: 10.1111/dom.16305
Abstract: Postprandial hyperlipidaemia (PPL), characterized by elevated triglyceride (TG) concentrations after a meal, is common in type 2 diabetes (T2D) and is often recognized as an independent cardiovascular risk factor. Here, we aimed to assess the… read more here.
Keywords: alirocumab postprandial; postprandial hyperlipidaemia; type diabetes; effect alirocumab ... See more keywords